The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trials.
Saved in:
| Title: | The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trials. |
|---|---|
| Authors: | Dickson SP; Pentara Corporation, Salt Lake City, UT, USA., Mallinckrodt C; Pentara Corporation, Salt Lake City, UT, USA., Burstein AH; Alzheimer's Drug Discovery Foundation, NY, NY, USA., Nisenbaum L; Alzheimer's Drug Discovery Foundation, NY, NY, USA., Fillit HM; Alzheimer's Drug Discovery Foundation, NY, NY, USA., Zhang C; Pentara Corporation, Salt Lake City, UT, USA., Hendrix SB; Pentara Corporation, Salt Lake City, UT, USA. Electronic address: shendrix@pentara.com. |
| Source: | The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2025 Dec; Vol. 12 (10), pp. 100391. Date of Electronic Publication: 2025 Oct 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101638820 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2426-0266 (Electronic) Linking ISSN: 22745807 NLM ISO Abbreviation: J Prev Alzheimers Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
